On November 4, 2026 OncoC4 Inc., a late clinical-stage biopharmaceutical company developing novel medicines for cancer, neurological and immunological diseases, reported encouraging Phase 1/2 results for cesalatamig (AI-081), its investigational PD-1/VEGF bispecific antibody, as monotherapy in patients with PD-(L)1-resistant/refractory non-small cell lung cancer (NSCLC). The findings will be presented in a late-breaking oral presentation at the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper) 2026 Annual Meeting in Phoenix, Arizona.
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Results reported in the SITC (Free SITC Whitepaper) abstract were derived from a pooled analysis of the global, multicenter, open-label BiPAVE-001 and BiPAVE-001 CN Phase 1/2 studies. As of July 31, 2026, the safety population included 103 patients with NSCLC who had received at least one dose of cesalatamig monotherapy at 1, 3, 10 or 20 mg/kg Q3W. Of these patients, 77 (75%) had non-squamous histology, 25 (24%) had squamous histology and one had unknown histology. 77% of patients had a baseline ECOG performance status of 1. The median number of prior therapy lines was two, and 42% of patients had received three or more prior lines. The safety profile was comparable between patients with squamous and non-squamous histology. The cesalatamig monotherapy is well tolerated at all dose levels.
Among 55 efficacy-evaluable patients with PD-(L)1 resistant/refractory NSCLC, cesalatamig monotherapy demonstrated dose-dependent antitumor activity. At 1 mg/kg (10 patients), 3 mg/kg (24 patients) and 10 mg/kg (21 patients) Q3W, investigator-assessed objective response rates (ORR) were 10%, 21% and 33%, respectively; disease control rates (DCR) were 40%, 67% and 90%, respectively. Responses to cesalatamig monotherapy were observed across PD-L1 expression levels. Exposure-response analyses support selection of 10 mg/kg Q3W as the dose for further development.
"Patients whose NSCLC progresses after immunotherapy and chemotherapy have limited effective treatment options," said Kai He, MD, PhD, principal investigator of the US BiPAVE-001 trial and the presenter of this study. "The responses and disease control observed with cesalatamig monotherapy are encouraging. Together with the manageable safety profile observed in these studies, these findings support further clinical evaluation in this setting."
"These findings strengthen the rationale for advancing cesalatamig monotherapy in previously treated NSCLC," said Yang Liu, PhD, Co-founder, Chief Executive Officer and Chief Scientific Officer of OncoC4. "The clinical results and exposure-response analyses support the selection of 10 mg/kg every three weeks as the dose for our planned pivotal study and provide a clear path forward for the continued development of cesalatamig in this setting."
Presentation Information
Title: Safety and Efficacy of Cesalatamig, a Novel PD-1/VEGF Bispecific Antibody, as Monotherapy in PD-(L)1–Resistant/Refractory NSCLC: Results from Global, Multicenter, Open-Label Phase 1/2 Studies
Abstract: #1187 (late-breaking oral presentation)
Presenter: Kai He, MD, PhD
Date: November 7, 2026
Meeting: 41st Annual Meeting of the Society for Immunotherapy of Cancer (SITC) (Free SITC Whitepaper), Phoenix, Arizona
Session: Clinical Oral Abstract Session 2, beginning at 1:45 PM MST
About Cesalatamig
Cesalatamig (AI-081) is an investigational, tetravalent PD-1/VEGF bispecific antibody designed to promote cooperative interactions between PD-1 and VEGF blockade in the tumor microenvironment. It combines high-affinity binding with Fc-silencing modifications intended to avoid depletion of PD-1-positive effector T cells. Cesalatamig is being evaluated as monotherapy and in combination with standard of care in the ongoing BiPAVE-001 clinical program. In September 2026, the U.S. FDA granted cesalatamig Fast Track designation for NSCLC that has progressed after concurrent or sequential PD-(L)1-targeted immunotherapy and platinum-based chemotherapy.
About BiPAVE-001
BiPAVE-001 (NCT06635785) and BiPAVE-001 CN (CTR20253261) are ongoing Phase 1/2 clinical trials evaluating the safety, pharmacokinetics, and efficacy of cesalatamig (AI-081), a bispecific antibody targeting PD-1 and VEGF, in patients with advanced solid tumors. OncoC4 is conducting these studies in the United States and China, respectively. Part A is the first-in-human Phase 1 dose-escalation and dose-expansion portion in patients with advanced solid tumors. Part B is the Phase 2 portion and includes dose-optimization trials evaluating AI-081 as monotherapy or in combination with standard of care in selected indications.
(Press release, OncoC4, NOV 6, 2026, View Source [SID1234674409])